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Newsroom
Dean Logan on Nexgen Litigation
Bloomberg spoke to Dean David Logan about hardball defense attempts to intimidate plaintiffs'
lawyers in Nexgen mass-tort litigation.
From BLOOMBERG: "Artificial-Knee Suits Targeting Zimmer Now Haunt Lawyers" by Alex
Nussbaum and David Voreacos
The story was also picked up by the ABA JOURNAL, Indianapolis Business Journal, and others.

August 8, 2011: Zimmer Holdings Inc. (ZMH), facing 78
product-liability lawsuits over its NexGen Flex artificial knees, has a rare strategy to defend the
product: target lawyers representing the patients.
Attorney Brett Emison, who wrote a blog post about failures in NexGen knees, got a letter from
Zimmer lawyers accusing him of “alarmist fear mongering” and demanding he stop.
“It’s a blatant attempt to try to frighten plaintiffs’ lawyers from pursuing these cases,” said
Emison of Lexington, Kentucky-based Langdon & Emison.
He’s not alone in drawing the legal wrath of the world’s biggest maker of replacement knees and
hips. The Warsaw, Indiana-based company has sued seven law firms this year and sent warning
letters to at least three more, saying their ads and Internet postings distorted the safety record of
its $1.8 billion-a-year knee business.

The pre-emptive strikes, begun in January, are an unusually
aggressive move, even in an orthopedics industry that’s become rife with litigation, Zimmer is
firing “a shot across the bow to these plaintiffs’ firms,” said Logan, dean at Roger Williams
University’s law school in Bristol, Rhode Island, in a telephone interview. “It’s like putting a
loaded gun on the table for negotiations. You’re saying, ‘Not only are we not going to give you
money, we’re going to go after you as well.’”
Correcting Record
The 84-year-old company is merely trying to correct the record about the 3 million NexGen
knees implanted worldwide since 1994, said Garry Clark, a Zimmer spokesman. In contrast to
the lawyers’ claims, joint-replacement databases in the U.K., Sweden and Australia show the
products have among the industry’s lowest failure rates, he said by e-mail. (U.S. implant
registries, started this year, haven’t released data yet.)
Plaintiffs’ lawyers “have a right to advertise truthfully,” Clark said. “They don’t have a right to
lie about our products.”
Zimmer fell $3.66, or 6.4 percent, to $53.90 at 4 p.m. in New York Stock Exchange composite
trading, on a day the Standard & Poor’s 500 Index tumbled 6.7 percent after S&P’s downgrade
of the U.S. credit rating. Before today, Zimmer had gained 7.2 percent this year.
The ads for the law firms followed a 2009 study that found one brand of NexGen knees had a
high rate of revision surgeries, repeat procedures needed to fix a failing implant. That prompted a
Michigan firm’s Web campaign saying NexGen was “linked to pain, failure and revision
surgery!”
Scarlet Letters
A Texas firm ran TV commercials warning in flashing scarlet letters of NexGen’s dangers and
inviting former patients to call a toll-free number for a free consultation, Zimmer’s lawsuit said.

Zimmer may eventually face 1,000 NexGen suits, said James Ronca, a Philadelphia attorney
representing patients.
The implant maker has also subpoenaed two firms, seeking information on their contacts with a
network of personal-injury attorneys. Four firms sued by Zimmer have settled and issued
retractions. The case against the remaining firms is ongoing.
Zimmer’s NexGen line includes more than 40 products. The knees combine four primary
components. Each has a tibial plate set on the lower leg bone, a femoral component attached to
the upper leg, a weight-bearing plastic insert between the two, and a replacement kneecap. Most
surgeons use a cement to attach the parts.
NexGen Component
The device that sparked the lawyers’ warnings, the NexGen CR-Flex Porous Femoral
Component, is designed for doctors who prefer not to use cement. Instead, the components have
textured or coated surfaces that encourage bone growth to fuse the implant in place.
Zimmer, in a May 2010 regulatory filing, said it had sold more than 150,000 porous femoral
components since the system’s U.S. approval in 2003. The product accounted for 2 percent of
knee revenue in 2009, the company said.
The CR-Flex’s safety was questioned as early as 2006 by Richard Berger, an orthopedic surgeon
at Rush University Medical Center in Chicago and a paid consultant to Zimmer, according to a
June 2010 New York Times article. Berger told the Times that he had warned the company about
cementless prostheses coming loose inside patients.
Two years later, Berger and a fellow Rush University surgeon, Craig Della Valle, released a 108patient study that found nine instances of femoral loosening and pain requiring a repeat
operation, a failure rate of 8.3 percent, according to Zimmer’s 2010 filing. Thirty-nine patients
showed evidence of loosening. The doctors said the problems “were not related to surgeon,
approach or patient type,” according to the filing.
Surgeons’ Meeting
Berger and Della Valle presented the data to a meeting of the American Association of
Orthopaedic Surgeons. The data haven’t been published in a peer-reviewed journal. Neither man
returned calls seeking comment.
Law firms pounced, publicizing the study in campaigns that suggested that all NexGen knees
were a problem, Zimmer said in its lawsuit. The ads have tarnished the company’s reputation and
hurt sales, it said.
In February, Zimmer sued three firms in federal court in South Bend, Indiana. It would later add
four more. The group included Houston-based Pulaski & Middleman LLC, whose TV ad said:
“Reports show the ZIMMER NEXGEN KNEE IMPLANT may have a failure rate of 9%,”
according to the complaint.

Another firm, Weller, Green Toups & Terrell LLP of Beaumont, Texas, wrote to doctors around
the U.S. in search of patients who might want to sue over Zimmer’s “defective knee implants.”
Retractions Issued
Both firms agreed to issue retractions, as did Gordon, Edelstein, Krepack, Grant, Felton &
Goldstein LLP of Los Angeles and Kresch Oliver of Southfield, Michigan.
“We have determined that the sources we previously relied upon to make claims about the
Zimmer NexGen Knee System do not support the statements or implications” in the ads,
according to a statement posted on Pulaski’s website.
A series of U.S. Supreme Court rulings have given attorneys wide latitude in advertising and
recruiting clients, said Logan, the Roger Williams dean. The campaigns can say anything
that’s not “provably false or misleading,” he said.
As personal-injury lawyers have grown more bold and numerous, corporations have gotten more
aggressive in their defense, Logan said.
Zimmer’s strategy “opens up a new front in the product- liability wars,” he said. “Their lawyers
are trying to get their arms around not being sued by hundreds or thousands of consumers of
their own products.”
‘Legitimate Discussion’
The lawsuit “is intended only to protect Zimmer and the patients and doctors who use its
products,” said Clark, the company spokesman. “Zimmer has not made any legal challenge to
advertising that is truthful and welcomes legitimate discussion based on fact.”
Zimmer’s moves contrast with those of Johnson & Johnson (JNJ), whose recall last year of
93,000 hip implants has spurred more than 2,000 lawsuits and widespread legal advertising on
the Internet.
The New Brunswick, New Jersey-based company hasn’t sued law firms, though it says some
advertising is “misleading and includes inaccuracies,” said Lorie Gawreluk, a spokeswoman for
J&J’s DePuy orthopedics unit. “We regularly contact these attorneys and request that they
correct such misinformation.”
Medically Reversible
NexGen components and surgical tools have been the subject of at least 58 recalls since 2002,
according to U.S. Food and Drug Administration records. None involved the CR-Flex or porous
femoral components. All were listed as Class 2 recalls, a category of defects expected to cause
only “temporary or medically reversible” health problems, the agency says.
Attorney Alyson Oliver of Kresch Oliver said she regrets that her firm agreed to the retraction.
Zimmer still hasn’t dropped the lawsuit, she said.

“It encouraged them because they were getting what they wanted,” she said in an interview.
“They were getting the larger advertising firms to tone down their messages or stop delivering
them.
“Our ads were legitimate,” Oliver said. “There was nothing erroneous about them.” The
retraction was “a business decision to try to get on with things so that this didn’t consume our
practice.”
Cease-and-Desist
The lawsuits and cease-and-desist letters may backfire, said attorney Sam Davis of Davis
Saperstein & Salomon in Teaneck, New Jersey. The company’s campaign has become a hot
topic at public seminars held by plaintiffs’ lawyers, he said.
“The strategic choice of attacking attorneys for minor inaccuracies is so counter-effective,” said
Davis. “Now at the Zimmer NexGen seminars, which are taking place all over the country,
they’re actually attracting more attorneys. Many plaintiffs’ lawyers believe it has attracted more
attention.”
Ronca, the Philadelphia attorney, said he received a cease- and-desist letter as well, based upon
an e-mail he sent to another plaintiffs’ lawyer.
“We told them that they could go jump in a lake because we didn’t misrepresent anything
because it wasn’t public,” said the attorney, of Anapol, Schwartz, Weiss, Cohan, Feldman &
Smalley.
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